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Background: Treatment of elderly patients with stage III NSCLC is
controversial. Limited data exist, as the elderly are underrepresented
in clinical trials.
Methods: After ethics approval, we performed a retrospective review
of 1372 stage III NSCLC patients treated at our institution during the
period 1997–2007. Patients with malignant effusions and microscopic
N2 discovered only postoperatively were excluded, leaving 740 who
were classified by treatment plan: palliative (palliative chemotherapy or
radiation [40 Gy]); nonsurgical multimodality (40 Gy radiation 
chemotherapy); or surgical multimodality (chemotherapy, radiation,
and surgery). Demographics, treatment, toxicity, and survival were
analyzed by age, 0 to 65 years, n 384; 66 to 75 years, n 256; 76
years, n  100, and compared using log-rank, univariate, and multi-
variate statistical tests.
Results: Patients older than 65 years were more likely to have poor
performance status (p  0.0001), multiple comorbidities (p 
0.0001), and to receive palliative therapy only (p  0.0001). Older
and younger patients treated with curative intent with nonsurgical
bimodality therapy or trimodality therapy including surgery had
similar rates of grade 3/4 toxicity (0–65 years, 39%; 66–75 years,
43%; 76 years, 5%; p  0.18) and toxic death (0–65 years, 4%;
66–75 years, 4%; 76 years, 0%; p  0.76). Survival was worse
with increasing age (p  0.0001), likely due to greater use of
palliative treatment in the elderly. When survival was analyzed for
patients treated with curative intent, there was no difference between
age groups for nonsurgical (p 0.32) or surgical (p 0.53) therapy.
Conclusion: In select fit elderly patients, combined modality ther-
apy is tolerable and is associated with survival similar to that of
younger patients.
Key Words:Locally advanced, Non-small cell lung cancer, Elderly,
Combined modality treatment, Trimodality, Stage III NSCLC.
(J Thorac Oncol. 2011;6: 537–544)
Non-small cell lung cancer (NSCLC), the leading cause ofcancer-related death in the industrialized world,1 is pri-
marily a disease of older people with a median age of
approximately 70 years at diagnosis.2,3 In the United States,
an estimated 109,720 individuals older than 70 years were
diagnosed with lung cancer in 2009.
Cancer clinical practice is guided by the results of clinical
trials, yet the elderly often are underrepresented or excluded
from these studies.4 This means that oncologists must extrapo-
late evidence from trials of younger patients and apply the
results to what may be a very different patient group biologi-
cally. Alternatively, they may rely on post hoc unplanned subset
analyses of older patients from larger trials,5,6 which also may
not be representative of the entire elderly population.
Locally advanced, stage III lung cancer may be treated
with curative intent with radical radiation alone, chemoradiation,
or chemoradiation and surgery. Several randomized trials com-
paring radiation alone to sequential and/or concurrent chemora-
diotherapy have demonstrated the superiority of combined mo-
dality therapy.7 Sequential chemotherapy and radiotherapy has
been compared with concurrent chemoradiotherapy, with con-
current therapy demonstrating superior survival.8 However,
combined modality treatment may be significantly more toxic
than radiation alone and may be less tolerable in elderly patients.
Regarding specific analyses of elderly patients receiving com-
bined modality therapy for locally advanced NSCLC, the evi-
dence is inconsistent. Some studies have shown greater toxicity
and less benefit9,10 in elderly subgroup analyses. However, more
modern studies have confirmed the feasibility and efficacy of
combined modality treatment, although more than one study has
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demonstrated that this is at the cost of increased toxicity in the
elderly.11
Within the bounds of tolerability, bimodality therapy
with concurrent or sequential chemoradiation is widely ac-
cepted as a standard of care for locally advanced NSCLC.
More controversial is the role of surgery in stage IIIA. A large
European randomized trial was negative,12 showing no survival
benefit for surgery compared with radiation after induction
chemotherapy. In contrast, a North American trial reported a
potential benefit for surgery in patients who required only
lobectomy,13 although no overall survival benefit for the addi-
tion of surgery to chemoradiation in the overall study group.
No consensus definition of elderly exists.14 Some in-
vestigators use age 65 years as a cut off, but the majority of
Western analyses specify 70 years, as it has been described as
the lower limit of senescence, being the age at which the
incidence of comorbidity increases sharply.15
Given the paucity of data to guide treatment of elderly
patients with locally advanced NSCLC, and the complex and
potentially toxic nature of such treatment, we performed this
retrospective analysis of 11 years of patient experience at the
University Health Network (UHN), including the Princess
Margaret Hospital, to examine the following question: in
locally advanced NSCLC, how should the elderly be treated
when cure is the goal?
PATIENTS AND METHODS
After Research Ethics Board approval, 1372 patients
were identified as presenting to the UHN with a diagnosis of
stage III NSCLC during the period 1997–2007 (Supplemental
Figure 1, http://links.lww.com/JTO/A58). All patients included
in the analysis received some of their treatment at UHN. The
electronic and when necessary paper records of these patients
were examined by four medical practitioners (L.E.C., A.S.,
K.B., and A.J.H.). Patients staged as IIIB NSCLC on the basis of
a malignant effusion (pleural or pericardial) and those with stage
III based on a postoperative pathological diagnosis of micro-
scopic N2 involvement were excluded. This was to ensure that
only clinical stage III patients at point of initial treatment
planning were included in the analysis.
Data were abstracted into predesigned electronic data
collection forms (Access, Microsoft, CA). Demographics,
including performance status (PS) and comorbidity (classified
according to Charlson comorbidity index [CCI], modified
according to Asmis et al.16), treatment intent, treatment de-
livery, and clinical outcomes, including toxicity and survival,
were collected.
Patients were classified as being planned for palliative
therapy (radiation with a radiation dose 40 Gy or chemother-
apy or both), radical radiation alone (40 Gy), or nonsurgical
multimodality therapy (platinum-based chemotherapy and radi-
ation40 Gy), which was further subdivided into concurrent or
sequential and surgical multimodality therapy, which consisted
of concurrent platinum-based chemoradiation as induction ther-
apy with a dose 45 Gy, followed by surgical resection. Most
patients receiving bimodality or trimodality therapy were treated
in the manner of the Intergroup 0139 trial13 (Supplemental Table
1) with concurrent etoposide/cisplatin and thoracic radiation
followed by two further cycles of platinum-based chemotherapy
alone after radiation and/or surgery.
Treatment delivery was recorded in terms of radiation
dose, chemotherapy cycles planned and received, and surgi-
cal procedure performed. Toxicity was recorded according to
the Common Terminology Criteria for Adverse Events v3.0
as well as surgical complications. Relapse and site of relapse
were recorded. Progression-free survival and overall survival
were measured from time of diagnosis.
Statistics
All analyses were generated using SAS software, Ver-
sion 9.2 TS Level 2MO of the SAS System for Windows,
copyright 2002–2008 (SAS Institute Inc., Cary, NC). Cases
with missing values were excluded.
Variable summaries were generated using proc freq and
proc means. Associations between age groups (0–65, 66–75,
and 76 years), patient demographics, and treatment-related
variables were tested using the trend test for binary variables,
the row mean score test for nominal variables with more than
two levels, and the correlation test for ordinal variables.
Fisher exact test and its extension, the Freeman-Halton test,
were used to test for associations between nominal variables.
The stratified Mantel-Haenszel mean score test was imple-
mented to control for CCI category when testing for associ-
ation between age group and treatment plan. Spearman’s
correlation was used to test for associations between contin-
uous variables.
Univariate associations between age and survival were
analyzed using the log-rank test, Kaplan-Meier plots, and
Cox models. Cox models were implemented to perform
multivariate analyses with age effects adjusted for Eastern
Cooperative Oncology Group PS (PS 1 versus 2), smoking
(never versus ever), sex, CCI (adapted for lung cancer ac-
cording to Asmis et al.16; 0 versus 1–2 versus 3), weight
loss (5% versus 5%), and histologic type (adenocarci-
noma versus other). Two versions of each model were im-
plemented, one with age in its categorical form and one with
age in its continuous form. Linearity and proportional hazards
assumptions were tested with quadratic terms and time-
varying covariates, respectively.
RESULTS
Demographics and Treatment Selection
Of 1372 charts examined, 740 patients met the inclu-
sion criteria (Table 1, Supplemental Figure 1). Age-specific
analyses were based on three age groups: 0 to 65 years, n 
384; 66 to 75 years, n 256; 76 years, n 100. There was
an association between increasing CCI and increasing age
(p  0.0001), and older patients were significantly more
likely to have worse PS (p  0.0001).
Fifteen patients, all older than 65 years, were offered no
anticancer therapy whatsoever (66–75 years, 2.7%; 76
years, 8%; p  0.0001) (Table 2, Supplemental Table 2).
Older patients also were more likely to be planned for
palliative treatment only (p  0.0001), most frequently pal-
liative-dose radiation rather than chemotherapy. In addition
to age, PS, CCI, and weight loss all were important determi-
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nants for treatment selection (Supplemental Table 3). Overall,
476 (64.0%) patients were planned for curative intent treat-
ment (0–65 years, 79.4%; 66–75 years, 55.5%; and 76
years, 29%; p  0.001). Furthermore, when we examined the
extreme elderly (patients older than 80 years, who constituted
only 5.9% of the entire cohort), the majority of patients in this
group were planned for palliative radiation, and no patient
was planned for concurrent bimodality or trimodality therapy.
However, when we examined all patients without known
adverse clinical prognostic features (good PS, minimal co-
morbidity, and no weight loss), treatment selection in older
patients was significantly more likely to be of palliative intent
than in younger patients (Table 2).
In patients planned for potentially curative therapy,
elderly patients were less likely to be offered multimodality
therapy that included surgery (p  0.03). Older patients were
not more likely to be planned for sequential therapy rather
than concurrent bimodality therapy (p  0.88).
To determine whether the motivation of treating phy-
sicians to treat older patients with curative intent changed
over time, we dichotomized the time period under study to
assess whether patients older than 65 years were more likely
to be selected for curative therapy and found no such asso-
ciation (1997–2002: 44.4%, 2003–2007: 51.7%; p  0.20).
Most patients who received chemoradiotherapy alone
or induction chemoradiotherapy and surgery were treated as
in the Intergroup 0139 study (Supplemental Table 1),13 but in
the final analysis of surgical patients, we also included those
who had surgery after induction chemotherapy or radiother-
apy alone, as these patients were known to have stage III
disease at diagnosis and either were entered onto a clinical
study or there was a technical reason for this treatment
selection.
Treatment Delivery
Treatment delivery is summarized in Table 3. There
was no difference among age groups in terms of number of
cycles of chemotherapy received. Furthermore, there was no
significant age effect on the delivery of consolidation or
adjuvant chemotherapy after completion of radical radiation
or surgery (p  0.35). We could identify no trend to suggest










Female 157 (40.9) 94 (36.7) 37 (37)
Male 227 (59.1) 162 (63.3) 63 (63)
ECOG PS 0.0001
0 92 (24.0) 53 (20.8) 14 (14)
1 246 (64.1) 132 (51.8) 49 (49)
2 37 (9.6) 47 (18.4) 25 (25)
2 9 (2.3) 23 (9.0) 12 (12)
Unknown  1
Smoking status 0.002
Smoker at diagnosis 166 (45.1) 89 (37.4) 21 (22.6)
Exsmoker 166 (44.7) 132 (55.5) 61 (65.6)
Never smoker 36 (9.8) 17 (71) 11 (11.8)
Unknown  41
Weight loss 0.063
5% 229 (65.0) 139 (63.8) 46 (53.5)
5% 120 (34.4) 79 (36.2) 40 (46.5)
Unknown  87
Histology 0.005
Adenocarcinoma 178 (46.4) 105 (41.0) 40 (40.0)
Squamous cell
carcinoma
120 (31.3) 95 (37.1) 40 (40.0)
Large cell carcinoma 39 (10.3) 15 (5.9) 3 (3.0)
NSCLC NOS 47 (12.2) 41 (16.0) 17 (17.0)
Stage 0.76
IIIA 194 (50.5) 128 (50.0) 53 (53.0)




0 235 (61.7) 100 (39.4) 27 (27)
1–2 121 (31.8) 114 (44.9) 45 (45)
3–4 21 (5.5) 36 (14.2) 23 (23)
5 4 (1.0) 4 5 (5)
Unknown  5
ECOG PS, Eastern Cooperative Oncology Group performance status; NSCLC,
non-small cell lung cancer; NOS, not otherwise specified.



















79 (20.6) 107 (41.8) 63 (71.0)
















Palliative intent 79 (20.6) 114 (44.5) 71 (71.0)
Curative intent 305 (79.4) 142 (55.5) 29 (29.0)
Planned treatment by age
in patients with PS
1, CCI 2, and
weight loss 5%
0.0001
Palliative intent 17 (8) 27 (26) 11 (46)
Curative intent 188 (92) 75 (74) 13 (54)
PS, performance status; CCI, Charlson comorbidity index.
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that elderly people received less radiation than younger pa-
tients; in fact, the median doses of radical radiation in the
bimodality groups actually was higher in the older age group
than in younger patients.
Among patients treated with preoperative chemoradia-
tion or chemotherapy, 24 did not proceed to surgery for the
following recorded reasons: 19 progressed, 2 died, 2 declined
surgery, and 1 patient’s PS declined, rendering him unfit for
surgery. There was no difference according to age (p 0.20).
The type of operation performed (lobectomy versus pneumo-
nectomy) was not affected by increasing age (p  0.28).
Response and Survival
There was no association observed between response
and increasing age (response rate: 0–65 years, 54%; 66–75
years, 58%; 76 years, 61.7%; p  0.32). In surgical pa-
tients, the complete pathological response rate was 21%;
there was no significant difference in pathological response
among age groups, although no patient older than 75 years
achieved complete pathological response (p  0.90).
Figure 1A shows overall survival by age for the entire
group. Older patients had significantly shorter survival (ad-
justed hazard ratio for patients aged 66–75 years compared
with patients aged 65 years or younger  1.56, 95% confi-
dence interval 1.31–1.86; hazard ratio for patients older than
75 years  1.96, 95% confidence interval 1.54–2.46; p 
0.0001). This is not surprising as patients older than 65 years
were more likely to be planned for palliative treatment. When
patients treated with curative intent (either with surgical or
nonsurgical multimodality treatment) were examined, there
was no statistically significant difference in survival (Figures
1B, C). Furthermore, in multivariate analysis (Table 4), after
controlling for PS, sex, smoking history, comorbidity, weight
loss, and treatment, there was no difference seen in overall
survival according to age (p  0.37). Cause of death was
known for 503 patients. Death for the majority of the patients
in each age group was due to lung cancer, and there was no
significant increase in death from other causes in the younger
patient group.
Toxicity
Treatment toxicity is summarized in Table 5. For pa-
tients undergoing multimodality treatment (with curative in-
tent), clinically meaningful (grade 3 and 4) hematologic
toxicity (Table 5A) was not associated with increasing age
(p  0.68) nor was nonhematological (Table 5B) toxicity
(p  0.81). Similarly, there was no statistically significant
association between surgical toxicity (Table 5C) and age. The
mean surgical stay for operations performed after induction
therapy was 8 days (range, 5–150), with no significant dif-
ference among age groups (p 0.19). Increasing age was not
associated with increased surgical mortality, eight patients
younger than 66 years, three patients younger than 76 years,
and no patients in the older than 76 years age groups died as
a complication of surgery.
There were 16 toxic deaths (associated with any compo-
nent of therapy); the likelihood of dying from treatment was not
significantly associated with increasing age (p  0.54).
DISCUSSION
In this analysis, we observed that the treatment offered
to older patients was significantly more likely to be of






Chemotherapy cycles delivered 0.17
Bimodality (including sequential
and concurrent)
1–2 42 (31.58) 16 (24.24) 6 (50.00)
3–4 91 (68.42) 50 (75.76) 6 (50.00)
Surgical multimodality 0.91
1–2 40 (31.75) 16 (35.56) 2 (28.57)
3–4 86 (68.25) 29 (64.44) 5 (71.43)
Consolidation chemotherapy delivered
(post bimodality concurrent and
trimodality therapy)
0.16
Yes 125 (45.8) 60 (53.1) 11 (55.0)










Radical radiation alone 60 (19–66) 55 (20–65) 64.5 (60–66)
Bimodality therapy (collapsed
sequential and concurrent)
61 (9–75) 61 (9–70) 64 (60–66)
Trimodality therapy with
surgery
45 (5–70) 45 (45–66) 45 (45–52)
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palliative nature, with only 29% of patients older than 75
years offered potentially curative therapy compared with
79.4% of patients younger than 66 years (p  0.0001).
Furthermore, when we examined the extreme elderly (pa-
tients older than 80 years), no patient was planned for
curative multimodality therapy. This may be due in part to
older patients being more likely to have a worse PS and more
comorbidity (p  0.0001 and p  0.0001, respectively).
There was also a trend (p  0.06) for older patients to have
experienced more weight loss at presentation, a known ad-
verse prognostic indicator. In the treatment of lung cancer
across all stages and age groups, PS, comorbidity, and weight
loss have been shown to correlate with poor outcomes.17
Indeed, the recently published American Society of Clinical
Oncology guidelines for treatment of advanced NSCLC18
recommend treating only those patients with PS 0 or 1. An
analysis of NCIC-CTG clinical trials in NSCLC16 correlated
worsening comorbidity with increasing age; furthermore,
worsening comorbidity was associated with worse survival out-
come that was independent of age. This was true, even in this
group of patients who met all the eligibility criteria for the
National Cancer Institute of Canada Clinical Trials Group trials.
It is impossible to tell how many patients were ex-
cluded from potentially curative treatment on the basis of age
alone. However, the treatment decisions reached by the treat-
ing physicians in our series may have been appropriate, as it
appears that a palliative approach was taken not only because
of age but also on the basis of other known adverse prognos-
tic indicators, including comorbidity and PS. However, it is
of note that when we examined those patients without known
adverse prognostic factors, the bias toward treating older
patients with palliative treatment regimens persisted. This is
a finding that seems to correlate with a large analysis of
patients with advanced NSCLC,19 where older patients were
observed to be more likely to receive no treatment. The
presence of ageism in medicine and in the treatment of
NSCLC is documented, with treatment plans being modified
and abridged for elderly patients with no clear rationale
applied.20
When we analyzed the group as a whole, the elderly
population demonstrated inferior survival, consistent with a
large previously published report.21 However, because the
elderly were more likely to have a worse PS and increasing
comorbidity,22 as might be expected, when these and other
potential confounding factors were controlled for in our
multivariate model, we did not see any difference in survival
between age groups in terms of worsening survival in patients
treated aggressively with curative intent. This was an obser-
vation seen in both the bimodality and trimodality treatment
groups. Furthermore, this is an observation that has been
reported in some,11,23,24 but not all,9,10 previous work. Some
reasons that have been given to account for this discrepancy
are patient selection, older methods of delivering radiother-
apy, and improvements over time in supportive care. Al-
though, in the multivariate model, there was no adverse
impact on overall survival with age, other clinical parameters,
such as weight loss and PS, were highly relevant.
When we examined treatment delivery, there was no
significant difference in the delivery of planned chemother-
apy or radiotherapy by age. This observation is in contrast to
previously reported studies5,25,26 where older patients re-
ceived less chemotherapy than their younger counterparts,
both in terms of lower mean total dose and fewer cycles
delivered. Although the biology of NSCLC and small cell
lung cancer (SCLC) are very different, the NCIC-CTG anal-
ysis of the influence of age on treatment outcomes in limited
SCLC26 is of some relevance, as patients in this analysis also
received cisplatin and etoposide delivered concurrently with
similar radiation doses to those used in the trimodality group
in this analysis. In the NCIC-CTG SCLC analysis, signifi-
cantly fewer elderly patients received three or more of the
planned six cycles of chemotherapy. Perhaps, combined mo-
dality regimens are perceived as so arduous that only the
fittest elderly were treated in this way in our center, and this
FIGURE 1. Overall survival according to age. A, Overall sur-
vival according to age—entire cohort. B, Overall survival ac-
cording to age for nonsurgical bimodality therapy. C, Overall
survival according to age—surgical multimodality therapy.
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may explain why treatment fidelity was so high in this current
analysis.
There was no statistically significant difference seen in
either hematological or nonhematological toxicity in this
study, although we did observe a higher incidence of grade 1
to 2 creatinine elevation that did not reach statistical signif-
icance. Three retrospective analyses of clinical trial patients
who showed equal survival but increased toxicity in the older
age cohorts were inconsistent with respect to the toxicities
observed in the elderly population, reporting increased neph-
rotoxicity, hematological toxicity, and esophagitis, respec-
tively.11,23,24 This may be because the elderly patients actu-
ally received differing doses than their younger counterparts,
as has been reported in the analyses of treatment of small cell
lung cancer in elderly patients,26 but data regarding treatment
delivery were not reported in these trials, and so it is impossible
to postulate further on the mechanism of differing toxicity
results. Deteriorating bone marrow function, which has been
demonstrated with increasing age,27 has been suggested as an
explanation for worsening hematological toxicity, and other
end-organ failure may result in reduced clearance of some
chemotherapy drugs. Currently, pharmacokinetics and pharma-
codynamics of oncology drugs are imperfectly understood in the
aged.28 Unfortunately, this sort of testing is often performed only
during the early stages of drug development, an area of inves-
tigation from which the elderly frequently are excluded.29
In the trimodality group who underwent induction treat-
ment followed by surgery in our analysis, the number of
surgical deaths was consistent with previously published
reports,12,13 and there was no excess surgical toxicity seen in
older patients, a finding that contrasts with a study from a
large tertiary referral center in the United States, demonstrat-
ing increased risk of atrial fibrillation in older patients after
lobectomy for lung cancer.30 The length of surgical stay in
our study also was not significantly longer for older patients,
consistent with a large British analysis of patients undergoing
resection for lung cancer.31 These patients, however, were
treated in our large tertiary referral center, where outcomes
for specialized surgical procedures may be better than in
centers with less experience.32 There may be further selection
bias in our cohort, as it is possible that only the fittest elderly
were referred. A counter argument to this, though, is that in
addition to the fit elderly, the most complex and difficult
cases are also referred to our center.
We return to the important question: how should we
treat the elderly when cure is the goal? At present, we rely on



















66–75 1.563 1.310–1.864 0.0001 1.161 0.944–1.427
76 1.947 1.542–2.459 1.088 0.810–1.462
Treatment plan 0.0001
Trimodality therapy 1 1
Bimodality therapy 1.62 1.29–2.03 0.0001 1.53 1.21–1.95
Radical dose radiation alone 3.02 1.99–4.57 2.14 1.29–3.53
Palliative treatment only 4.30 3.44–5.38 3.57 2.71–4.69
ECOG PS 0.008
0–1 1 0.0001 1 1.19–1.97
2 2.77 2.29–3.35 1.53
Smoking status 0.7725
Never smoker 1 0.002 1 0.77–1.43
Ever smoker 1.25 0.94–1.66 1.05
Sex 0.3128
Female 1 0.316 1 0.91–1.34
Male 1.25 1.06–1.47 1.10
Comorbidity 0.9383
CCI 0 1 1
CCI 1–2 1.40 1.18–1.67 0.0001 0.95 0.81–1.22
CCI 3 2.00 1.56–2.56 0.94 0.68–1.32
Weight loss 0.0001
Weight loss 5% 1 0.0001 1 1.33–1.95
Weight loss 5% 1.99 1.67–2.37 1.61
Histology 0.902
Adenocarcinoma 1 0.006 1
Nonadenocarcinoma 1.30 1.11–1.53 1.01 0.82–1.19
CCI, Charlson comorbidity index; ECOG PS, Eastern Cooperative Oncology Group performance status.
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n (%) p n
Hematological toxicity
Anemia 0.638 427
N  277 (0–65)* 1–2 149 (53.8) 72 (59.0) 11 (39.3)
N  122 (66–75)* 3–4 17 (6.1) 10 (8.2) 2 (7.1)
76  6
Neutropenia 0.745 428
N  276 (0–65)* 1–2 81 (29.3) 29 (23.4) 4 (14.3)
N  124 (66–75)* 3–4 39 (14.1) 26 (21.0) 2 (7.1)
N  28 (76)*
Thrombocytopenia 0.533 424
N  273 (0–65)* 1–2 45 (16.5) 24 (19.5) 4 (14.3)
N  123 (66–75)* 3–4 4 (1.5) 2 (1.6) 1 (3.6)
N  28 (76)*
Febrile neutropenia 0.127 457
N  296 (0–65)* 1–2 11 (3.7) 4 (3.0) 0 (0.0)
N  132 (66–75)* 3–4 6 (2.0) 8 (6.1) 1 (3.4)
N  29 (76)*
Nonhematological toxicity
Nausea 0.875 459
N  297 (0–65)* 1–2 46 (15.5) 19 (14.3) 2 (6.9)
N  133 (66–75)* 3–4 18 (6.1) 9 (6.8) 1 (3.4)
N  29 (76)*
Vomiting 0.544 459
N  297 (0–65)* 1–2 31 (10.4) 9 (6.8) 2 (6.9)
N  133 (66–75)* 3–4 11 (3.7) 5 (3.8) 0
N  29 (76)*
Esophagitis 0.604 462
N  298 (0–65)* 1–2 96 (32.2) 47 (34.8) 9 (31.0)
N  135 (66–75)* 3–4 29 (9.7) 14 (10.4) 1 (3.4)
N  29 (76)*
Creatinine elevation 0.123 476
N  305 (0–65)* 1–2 42 (13.8) 32 (22.5) 9 (31.0)
N  142 (66–75)* 3–4 0 3 (2.1) 0
N  29 (76)*
Pneumonitis 0.089 459
N  297 (0–65)* 1–2 33 (11.1) 10 (7.5) 5 (17.2)
N  133 (66–75)* 3–4 14 (4.7) 14 (10.5) 2 (6.9)










(N  6) p
Surgical toxicity
Infection (N  161*) 0.795
0–65  116 21 (18.1%) 9 (23.1%) 1 (16.7%)
66–75  38
76  6
Arrhythmia (N  161*) 0.285
0–65  116 12 (10.3%) 1 (2.6%) 0
66–75  38
76  6
Air leak (N  161*) 0.826
0–65  116 8 (6.8%) 3 (7.9%) 0
66–75  38
76  6
Venous thromboembolism (N  161*) 0.208
0–65  116 4 (3.4%) 2 (5.3%) 1 (16.7%)
66–75  38
76  6
Fistula (N  161*) 1.000
0–65  116 3 (2.6%) 1 (2.6%) 0
66–75  38
*Number of patients for whom data are available.
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a relatively unscientific but effective method of employing
clinical acumen and multidisciplinary discussion. There are
comprehensive geriatric assessments to aid treatment plan-
ning for the elderly33 that are employed in various institu-
tions, but these frequently are time consuming, incompletely
validated, out of reach of many centers, and therefore, at
present, not universally employed. Specific elderly trials34
have been mounted as one way to guide treatment of elderly
patients in a more scientific way; however, there have been
no such trials for patients with stage III NSCLC.
Our study demonstrates that age alone should not be a
reason to deny curative treatment to elderly patients aged 65
to 80 years with locally advanced NSCLC. On the basis of
our analysis, we cannot draw the same conclusions for older
patients. Better, standardized ways of evaluating elderly pa-
tients’ ability to withstand treatment is an urgent consider-
ation as our population is aging, and this treatment dilemma
is one that will be encountered with increasing frequency by
thoracic oncologists of all disciplines.
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